Exelixis, Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2024, ended March 29, 2024 (presented in the filing as March 31, 2024); comparative period ended March 31, 2023. The request metadata says “2023 Q1,” but the filing is for 2024 Q1.
Business context
Exelixis is an oncology company with four marketed products. CABOMETYX and COMETRIQ contain cabozantinib; CABOMETYX accounts for nearly all product revenue. The company also earns collaboration and license revenue, including from cabozantinib commercialization outside the United States. Its pipeline includes zanzalintinib, XB002 and XL309, among other candidates.
Key financial results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $425.2 million | $408.8 million | +4% |
| Net product revenue | $378.5 million | $363.4 million | +4% |
| Income from operations | $29.5 million | $28.8 million | +2% |
| Net income | $37.3 million | $40.0 million | -7% |
| Diluted earnings per share | $0.12 | $0.12 | Unchanged |
| Operating cash flow | $68.8 million | $84.4 million | -18% |
CABOMETYX net revenue was $376.4 million, up 4%; management attributed growth mainly to 5% higher unit volume, partly offset by a 1% decline in average net selling price. Gross product revenue grew 8%, while discounts and allowances rose 17%. License revenue increased 17% to $44.7 million, primarily reflecting higher Ipsen cabozantinib royalties; collaboration services revenue fell 71% to $2.0 million, largely due to lower development cost reimbursements.
Cost of goods sold rose 48% to $21.3 million, and gross margin declined to 94% from 96%. Research and development expense decreased 3% to $227.7 million: lower discovery and licensing costs were partly offset by higher clinical trial and development costs. Selling, general and administrative expense fell 13% to $114.0 million. The effective tax rate increased to 24.3% from 17.1%. Net income declined despite higher revenue, reflecting restructuring charges, increased cost of goods sold and higher taxes.
Cash, liquidity and capital
Cash, cash equivalents and investments totaled $1.593 billion at March 31, 2024, down from $1.724 billion at December 31, 2023. Working capital was $919.4 million. Operating cash flow was $68.8 million; investing activities provided $111.8 million, primarily reflecting investment maturities net of purchases; financing activities used $184.0 million, largely for share repurchases. Cash and cash equivalents alone were $259.6 million. The balance sheet reports no debt line item; the filing text does not provide a separate debt total. Management expects available liquidity and anticipated revenues to fund operations for at least 12 months and thereafter for the foreseeable future.
Material changes and unusual items
- The company recorded $32.8 million of restructuring expense in Q1 under a plan to reduce its workforce, reduce real-estate commitments and terminate certain licensing partnerships. The plan was expected to be substantially complete in Q2 2024; estimated total plan costs were $33.0 million.
- Exelixis repurchased 8.638 million shares for an aggregate purchase price of $190.7 million under a $450 million authorization running through year-end 2024; approximately $259.3 million remained authorized. The cash flow statement reports $185.4 million of repurchase payments during the quarter.
- The company terminated certain in-licensing arrangements, with terminations expected to take effect in April 2024. Potential future milestone obligations under active in-licensing and asset-purchase arrangements were disclosed at up to $509.6 million for development, $365.4 million for regulatory and $2.5 billion for commercial milestones, in aggregate per product or target.
Outlook, commentary and risks
Management projected net product revenue could increase during the remainder of 2024, while discounts and allowances as a percentage of gross sales could also rise. It expected collaboration services revenue to decrease, clinical trial costs to increase, and research and development and selling, general and administrative expenses to decrease versus the comparable prior-year period, in part due to restructuring. No specific full-year revenue or earnings guidance is provided in the filing text.
Development priorities include zanzalintinib, XB002 and XL309. CONTACT-02 met its progression-free-survival endpoint, but interim overall-survival data were immature and did not meet the threshold for statistical significance; a further analysis was anticipated later in 2024. Exelixis was discussing a potential regulatory submission with the FDA. The company was also discussing potential submissions based on the CABINET study results.
Key risks include reliance on CABOMETYX commercial success, competition and reimbursement or pricing pressure, uncertainty in clinical and regulatory outcomes, and potential generic competition. MSN II litigation was awaiting judgment, expected in the first half of 2024. Cipla amended its ANDA to seek additional CABOMETYX dosage strengths, and Exelixis was evaluating the additional certifications. The company said an early generic launch could materially reduce U.S. CABOMETYX revenue; it could not estimate the likelihood or amount of any potential loss. Teva’s settlement provides for a possible U.S. generic license beginning January 1, 2031, subject to FDA approval and stated conditions.
The filing reported no material changes to the risk factors in the 2023 Form 10-K. Management stated disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Track CABOMETYX volume, net pricing, payer discounts and the contribution from international royalties.
- Monitor outcomes and timing for CONTACT-02 overall survival, CABINET regulatory discussions, and key zanzalintinib and XB002 trials.
- Review developments in MSN II and Cipla patent proceedings, and the implications of the Teva settlement.
- Assess execution and final costs of the restructuring, including the effects on research priorities and spending.
- Reconcile the disclosed $190.7 million repurchase purchase price with the $185.4 million of cash payments reported for the quarter, and monitor remaining authorization and liquidity.